Inhibition of the human mitochondrial ClpP protease as a novel strategy against multiple myeloma

被引：0
作者：
Patrone, M. [1 ]
Di Pisa, F. [1 ]
Tosatto, L. [2 ]
Swuec, P. [2 ]
Perini, T. [1 ]
Resnati, M. [1 ]
Del Grosso, Erika [3 ]
Yudin, A. K. [4 ]
Schimmer, A. D. [5 ]
Cenci, S. [1 ]
Coscia, F. [2 ]
Degano, M. [1 ]
机构：
[1] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy
[2] Human Technopole, Viale Rita Levi Montalcini 1, I-20157 Milan, Italy
[3] Univ Piemonte Orientale, Dipartimento Sci Farmaco, Lgo Donegani 2, I-28100 Novara, Italy
[4] Univ Toronto, Dept Chem, Davenport Res Labs, 80 St George St, Toronto, ON M5S 3H6, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
来源：
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting CD47 As a Novel Therapeutic Strategy in Multiple Myeloma
    Muz, Barbara
    Kusdono, Hubert D.
    King, Justin
    Kohnen, Daniel
    Fiala, Mark A.
    Vij, Ravi
    Capoccia, Ben
    Manning, Pamela T.
    Salama, Noha Nabil
    Azab, Abdel Kareem
    BLOOD, 2017, 130
  • [42] Dual BET/kinase inhibitors as a novel strategy for the treatment of multiple myeloma
    Tauro, Marilena
    Ayaz, Muhammad
    Lawrence, Harshani R.
    Lawrence, Nicholas J.
    Shain, Kenneth H.
    Schonbrunn, Ernst
    Lynch, Conor C.
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Protease inhibition by novel fluoropeptidomimetics: A mechanism-based design strategy.
    Kotra, LP
    Annedi, SC
    Majumder, K
    Samson, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U211 - U211
  • [44] PDK1 inhibition is a novel therapeutic target in multiple myeloma
    S Fujiwara
    Y Kawano
    H Yuki
    Y Okuno
    K Nosaka
    H Mitsuya
    H Hata
    British Journal of Cancer, 2013, 108 : 170 - 178
  • [45] PDK1 inhibition is a novel therapeutic target in multiple myeloma
    Fujiwara, S.
    Kawano, Y.
    Yuki, H.
    Okuno, Y.
    Nosaka, K.
    Mitsuya, H.
    Hata, H.
    BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 170 - 178
  • [46] Inhibition of CD47 as a Novel Cancer Immunotherapy for Multiple Myeloma
    Sun, Jennifer
    Muz, Barbara
    Alhallak, Kinan
    King, Justin
    Kohnen, Daniel
    Fiala, Mark
    Vij, Ravi
    Azab, Kareem
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E153 - E154
  • [47] Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma
    Sharma, Aditi
    Achreja, Abhinav
    Nair, Remya
    Gupta, Pulkit
    Edgar, Claudia L.
    Animasahun, Olamide
    Mitta, Anjali
    Dwivedi, Bhakti
    Bhasin, Manoj
    Gupta, Vikas A.
    Barwick, Benjamin G.
    Matulis, Shannon M.
    Lonial, Sagar
    Boise, Lawrence H.
    Jaye, David L.
    Wiita, Arun P.
    Nooka, Ajay K.
    Nagrath, Deepak
    Shanmugam, Mala
    BLOOD, 2021, 138
  • [48] Aquaporin 3 inhibition suppresses the mitochondrial respiration rate and viability of multiple myeloma cells
    Tanaka, Manami
    Yasui, Masato
    Hara-Chikuma, Mariko
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 676 : 158 - 164
  • [49] Potentiating T cell activity against multiple myeloma through SUMOylation inhibition
    Du, Li
    Awuah, Dennis
    Liu, Wei
    Caserta, Enrico
    Pichiorri, Flavia
    Wang, Xiuli
    Rosen, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S1 - S1
  • [50] Potent human ClpP protease agonists with anticancer properties bind the enzyme with improved structural complementarity and alter the mitochondrial N-terminome
    Mabanglo, Mark F.
    Wong, Keith S.
    Barghash, Marim M.
    Graves, Lee M.
    Iwanowicz, Edwin J.
    Houry, Walid A.
    CANCER RESEARCH, 2023, 83 (07)
12345